Applied Biologics submits CAMPX Trial abstract to SAWC Fall 2026

Updated data from the 222-patient RCT showed XWRAP nearly doubled complete wound closure rates versus standard of care alone at 12 weeks.

The Biotech Times Editorial Team By The Biotech Times Editorial Team
A gloved hand removes a clear plastic film from a raw skin lesion on a forearm in a brightly lit medical examination room with a large window and medical equipment in the background.

Applied Biologics has submitted an abstract of updated results from its CAMPX Trial to the Symposium on Advanced Wound Care (SAWC) Fall 2026, reporting that its XWRAP single-layer amniotic membrane product significantly outperformed standard of care in patients with chronic diabetic foot ulcers.

The multicentre, randomised controlled trial enrolled 222 subjects with Wagner Grade 1 or 2 diabetic foot ulcers. Participants were split between XWRAP plus standard of care (113 patients) and standard of care alone (109 patients), with complete wound closure within 12 weeks as the primary measure.

Trial results

In the intent-to-treat analysis, 30.9% of patients in the XWRAP arm achieved complete wound closure within the 12-week treatment window, compared with 17.5% in the control arm. That represents a 13.4 percentage-point absolute improvement, with a 95% confidence interval of 1.9% to 24.5% and a p-value of 0.023. The XWRAP group also showed superior wound-size reduction across the study period, with a median percent area reduction of 55.1% versus 36.4% in the control group.

Thomas Serena, MD, founder of SerenaGroup and principal investigator of the CAMPX Trial, said the improvements in both closure rates and area reduction "are clinically meaningful and merit further evaluation and dissemination within the wound care community."

Edward Britt, chief executive of Applied Biologics, said the abstract submission reflects the company's commitment to generating "high-quality, peer-reviewed clinical evidence" to support treatment decisions in chronic wound management.

Market context

Diabetic foot ulcers represent one of the most costly and clinically burdensome complications of diabetes, with an estimated 15 to 25 per cent of patients with diabetes developing a foot ulcer at some point during their lifetime. Poor healing outcomes drive significant hospitalisation costs and remain a leading cause of non-traumatic lower-limb amputations globally. The market for advanced wound care products addressing this population is competitive, with a range of amniotic and placental tissue allografts, collagen matrices, and bioengineered skin substitutes vying for clinical adoption.

Amniotic membrane products occupy a growing niche within this landscape, valued for their reported anti-inflammatory and pro-regenerative properties. Several companies are active in the placental-tissue allograft segment, spanning both single-layer and multi-layer constructs. Applied Biologics is positioning XWRAP on the basis of prospective RCT evidence, which remains relatively scarce in the advanced wound care category. The CAMPX results, if accepted for presentation at SAWC, would give the product a platform to differentiate on clinical rigour at one of the sector's principal annual meetings.

The absolute improvement in complete closure rates is modest at 13.4 percentage points, and the confidence interval is wide, suggesting the result, while statistically significant, was achieved against a relatively low standard-of-care bar. Clinicians and payers will likely look for longer follow-up data and health-economic modelling before making formulary commitments. Applied Biologics said it expects to provide further updates on presentation and publication timelines as they become available.

Sector

Topic

Geography